Cargando…
Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells
The lysine-specific demethylase 1 (LSD1) is overexpressed in several cancers including rhabdomyosarcoma (RMS). However, little is yet known about whether or not LSD1 may serve as therapeutic target in RMS. We therefore investigated the potential of LSD1 inhibitors alone or in combination with other...
Autores principales: | Haydn, Tinka, Metzger, Eric, Schuele, Roland, Fulda, Simone |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520898/ https://www.ncbi.nlm.nih.gov/pubmed/28617441 http://dx.doi.org/10.1038/cddis.2017.239 |
Ejemplares similares
-
JNJ-26481585 primes rhabdomyosarcoma cells for chemotherapeutics by engaging the mitochondrial pathway of apoptosis
por: Heinicke, Ulrike, et al.
Publicado: (2015) -
Cell Death Pathways as Therapeutic Targets in Rhabdomyosarcoma
por: Fulda, Simone
Publicado: (2012) -
Novel dual LSD1/HDAC6 inhibitor for the treatment of cancer
por: Gajendran, Chandru, et al.
Publicado: (2023) -
Synergistic Re-Activation of Epigenetically Silenced Genes by Combinatorial Inhibition of DNMTs and LSD1 in Cancer Cells
por: Han, Han, et al.
Publicado: (2013) -
LSD1 promotes oxidative metabolism of white adipose tissue
por: Duteil, Delphine, et al.
Publicado: (2014)